Literature DB >> 32422340

Tissue-resident memory CD8+ T cells in cancer immunology and immunotherapy.

Ting Wang1, Yifei Shen2, Sophie Luyten2, Yexin Yang2, Xiaodong Jiang3.   

Abstract

Memory T cells can be generated and remain long-term in different tissues following infection or immunization. Tissue-resident memory T (TRM) cells are a unique group of memory T cells that form and persist mainly in peripheral non-lymphoid organs. Unlike effector or central memory T (TEM or TCM) cells, TRM cells do not circulate to the blood but can provide a rapid and robust local response to re-infection. Recently, a large body of clinical studies has shown that CD103+ CD8+ TRM-like cells also exist intratumorally and strongly correlate with favorable prognosis in cancer patients. Cancer vaccine-induced CD103+ CD8+ TRM cells have been reported to suppress tumor growth in mouse models. This suggests that CD8+ TRM-like cells play a crucial role in cancer immunosurveillance and immunotherapy. In this review, we focus on the features and cytotoxic mechanisms of CD8+ TRM-like cells in multiple solid tumors and discuss their potential implications for cancer immunotherapy. We believe a better understanding of the generation, function, and longevity of CD8+ TRM-like cells in the tumor microenvironment will provide new insights for cancer immunotherapies.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adoptive cellular therapy (ACT); Chimeric antigen receptor (CAR); Immune checkpoint blockade (ICB); Tissue-resident memory T (T(RM)) cells; Tumor microenvironment (TME)

Mesh:

Substances:

Year:  2020        PMID: 32422340     DOI: 10.1016/j.phrs.2020.104876

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  7 in total

1.  Distribution, phenotype, functional and clinical relevance of CD8+CD103+ tissue-resident memory T cells in human gastric cancer.

Authors:  Yang Shen; Xiao-Long Li; Yu-Xian Li; Zhi-Guo Shan; Yong-Liang Zhao; Ping Cheng; Zhuo Zhao; Jin-Yu Zhang; Weisan Chen; Yuan Zhuang; Dai-Yuan Ma; Quan-Ming Zou; Yuan Qiu; Liu-Sheng Peng
Journal:  Cancer Immunol Immunother       Date:  2021-11-12       Impact factor: 6.968

Review 2.  Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy.

Authors:  Qin Qiu; Yuqi Lin; Yucui Ma; Xiaoling Li; Juan Liang; Zhiyan Chen; Kaifeng Liu; Yuge Huang; Hui Luo; Riming Huang; Lianxiang Luo
Journal:  Front Immunol       Date:  2021-01-07       Impact factor: 7.561

Review 3.  Precision-Cut Tumor Slices (PCTS) as an Ex Vivo Model in Immunotherapy Research.

Authors:  Paraskevi Dimou; Sumita Trivedi; Maria Liousia; Reena R D'Souza; Astero Klampatsa
Journal:  Antibodies (Basel)       Date:  2022-04-06

Review 4.  Tissue-resident memory T cells in chronic liver diseases: Phenotype, development and function.

Authors:  Yikang Li; Zhengrui You; Ruqi Tang; Xiong Ma
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

5.  FOXP family DNA methylation correlates with immune infiltration and prognostic value in NSCLC.

Authors:  Dong-Mei Hu; Wen-Di Zhang; Zhuang-E Shi; Meng-Yu Zhang; Rui Li; Qing-Xiang Wang; Xiu-Li Ji; Yi-Qing Qu
Journal:  Front Genet       Date:  2022-09-09       Impact factor: 4.772

6.  Tumor Extracellular Matrix Stiffness Promptly Modulates the Phenotype and Gene Expression of Infiltrating T Lymphocytes.

Authors:  Maila Chirivì; Fabio Maiullari; Marika Milan; Dario Presutti; Chiara Cordiglieri; Mariacristina Crosti; Maria Lucia Sarnicola; Andrea Soluri; Marina Volpi; Wojciech Święszkowski; Daniele Prati; Marta Rizzi; Marco Costantini; Dror Seliktar; Chiara Parisi; Claudia Bearzi; Roberto Rizzi
Journal:  Int J Mol Sci       Date:  2021-05-30       Impact factor: 5.923

7.  CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer.

Authors:  Pin Wu; Yongyuan Chen; Zhongwei Xin; Xiaoke Chen; Lufeng Zhao; Mingjie Lin; Zhixing Hao; Di Chen; Dang Wu; Ying Chai
Journal:  Cancer Immunol Immunother       Date:  2021-05-02       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.